12:53 PM
 | 
May 12, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS). Teva said it has no plans to further develop laquinimod to treat RRMS.

Laquinimod missed the primary endpoint of improving time to confirmed disability progression (CDP) after ≥3 months vs. placebo (HR=0.937; p=0.7057). CDP was...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >